STAT-Diagnostica Attracts Siemens Venture Capital as a New Investor - Gilde Healthcare

STAT-Diagnostica Attracts Siemens Venture Capital as a New Investor

October 5, 2016

Funding will be used to support go-to-market activities in Europe

BARCELONA – Medical diagnostics company STAT-Diagnostica has closed an extension of its Series C financing with Siemens Venture Capital. The additional proceeds will be used to support the 2017 European launch of its DiagCORE Near Patient Testing system. Led by Gilde Healthcare, the Series C financing round also drew participation from existing investors, including Kurma Partners; Ysios Capital; Idinvest Partners; Boehringer Ingelheim Venture Fund; Caixa Capital Risc; and Axis.

“STAT-Diagnostica has an exciting technology that could significantly advance the diagnosis and triage of infectious diseases. We are impressed with the team and look forward to working with them in bringing DiagCORE to clinicians treating patients around the world,” said Ralf Schnell, CEO of Siemens Venture Capital.

DiagCORE is a fully integrated molecular and immunoassay diagnostics system that delivers lab-like performance in just one step, providing unrivaled usability for true walk-away diagnostics. DiagCORE performs all sample prep steps on board for a wide range of sample types (e.g., whole blood, swabs, BAL, stool, sputum) while offering up to 48-multiplex capabilities via real-time PCR. Time to results can be as low as 30 and up to 80 minutes, depending on the assay type. DiagCORE’s rapid performance is expected to improve clinical decision making and deliver better patient management and cost savings to the healthcare system.

“We are delighted that Siemens Venture Capital has become part of our investor base. Their participation is a terrific validation of the company’s vision and the work of our entire team,” said Jordi Carrera, CEO and co-founder of STAT-Diagnostica. “Together, we believe in DiagCORE’s unique potential to meet the changing and fast growing molecular diagnostics market dynamics.”

STAT-Diagnostica plans to target a range of decentralized testing environments with DiagCORE, including critical care and emergency medicine units within hospitals. The system will also have CLIA-waivable features that will allow it to be used in clinics and physician offices.

 

About STAT-Diagnostica
Founded in 2010 in Barcelona, STAT-Diagnostica is focused on the development of Near Patient Testing solutions where fast and accurate diagnostic results are needed. Its DiagCORE in vitro diagnostic system is a versatile, easy-to-use platform that consolidates molecular and immunoassay techniques in a single device.

STAT-DIAGNOSTICA MEDIA CONTACT/U.S.:
Laura Nobles
Nobles Global Communications
310-795-0497
laura@noblesgc.com

STAT-DIAGNOSTICA MEDIA CONTACT/EUROPE:
Giorgio Pirazinni
Medeuronet
+33 (0) 6 42 41 30 55
gpirazzini@medeuronet.com

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022